For AD Missling is still in considering to have an AA pathways discussion with FDA. Those considerations are linked to procrastinating over how best to represent a so far unusual way for the FDA to look at the P2b/3 results and probably further biomarkers than the two in the recent PR.
Rett in principle could be filed this year provided the results are clear in a to protocol traditional manner and a proper rolling submission has been taking place. Maybe Anavex have been filling on a rolling basis and maybe the results are strong with straightforward traditional TLR/TLD, but given precedence my best guess is Q1 next year.